The authors' response: Propofol in COVID 19: From basic science to clinical impact.

Soh, Mitsuhito; Hifumi, Toru; Isokawa, Shutaro; Shimizu, Masato; Otani, Norio; Ishimatsu, Shinichi

Soh, Mitsuhito; Hifumi, Toru; Isokawa, Shutaro; Shimizu, Masato; Otani, Norio; Ishimatsu, Shinichi.

Soh M; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Hifumi T; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan. Electronic address: hifumitoru@gmail.com.
Isokawa S; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Shimizu M; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Otani N; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Ishimatsu S; Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.

Am J Emerg Med ; 45: 528, 2021 07.

Article in English | MEDLINE | ID: covidwho-655310

Subject(s)

COVID-19; Neuroleptic Malignant Syndrome; Propofol; Humans; Hypnotics and Sedatives; SARS-CoV-2

Keywords

COVID-19; Neuroleptic malignant syndrome; Propofol

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Propofol / COVID-19 / Neuroleptic Malignant Syndrome Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Am J Emerg Med Year: 2021 Document Type: Article Affiliation country: J.ajem.2020.07.006

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google